Search

PROF John Seymour

Positions

Honorary, The Sir Peter MacCallum Department of Oncology
Honorary, Medicine - St Vincent's Hospital

Publications

Selected publications

2019
- Journal Articles
  - Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Leukemia and Lymphoma. 2019
  - Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography Reply. Journal of Clinical Oncology. 37. 2019
  - Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 134. 2019
- Journal Articles Refereed
  - A Retrospective Evaluation of Risk of Peripartum Cardiac Dysfunction in Survivors of Childhood, Adolescent and Young Adult Malignancies. Cancers. 11. 2019
  - A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. Hematological Oncology. 37. 2019
  - A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. Leukemia and Lymphoma. 60. 2019
  - Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discovery. 9. 2019
  - Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 104. 2019
  - Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. Haematologica. 104. 2019
  - Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. 2019
  - Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma. 2019
  - Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nature Medicine. 25. 2019
  - Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 134. 2019
  - Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology. 37. 2019
  - High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing. Leukemia and Lymphoma. 2019
  - Outcome of patients with early-stage follicular lymphoma staged with F-18-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone. European Journal of Nuclear Medicine and Molecular Imaging. 46. 2019
  - Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. The Lancet Haematology. 6. 2019
  - Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. British Journal of Clinical Pharmacology. 85. 2019
  - The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment. Cancers. 11. 2019
  - The trials and tribulations of conducting an m-health pilot randomized controlled trial to improve oral cancer therapy adherence: recommendations for future multisite, non-drug clinical trials.. BMC Research Notes. 12. 2019
- Journal Articles Unrefereed Letters or Notes
  - Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients With Cancer-Related Immunosuppression. Journal of Clinical Oncology. 37. 2019
  - Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. British Journal of Haematology. 186. 2019
  - Venetoclax, the First BCL-2 Inhibitor for Use in Patients With Chronic Lymphocytic Leukemia 2019
2018
- Journal Articles
  - Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine. 378. 2018
- Journal Articles Refereed
  - A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 132. 2018
  - Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. The Lancet Haematology. 5. 2018
  - Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research. 24. 2018
  - Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018
  - Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. New England Journal of Medicine. 378. 2018
  - Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology. 36. 2018
  - JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias. Genes & Development. 32. 2018
  - Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 32. 2018
  - Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leukemia and Lymphoma. 59. 2018
  - Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). Journal of Clinical Oncology. 36. 2018
  - Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Annals of Oncology. 29. 2018
  - Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. Journal of Clinical Oncology. 36. 2018
  - Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas. Clinical Cancer Research. 24. 2018
  - Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. European Journal of Cancer. 93. 2018
  - Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. Journal of Clinical Oncology. 36. 2018
  - iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 131. 2018
- Journal Articles Unrefereed
  - Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies. Blood Cancer Journal. 8. 2018
- Journal Articles Unrefereed Letters or Notes
  - Management of Pregnancy in Women With Chronic Myeloid Leukemia. Journal of Clinical Oncology. 36. 2018
  - Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. Journal of Clinical Oncology. 36. 2018
- Other Refereed Contribution to Refereed Journals
  - "Reversible" myelodysplastic syndrome or ineffectual clonal haematopoiesis? - add(6p) myeloid neoplasm with a spontaneous cytogenetic remission. Leukemia Research. 73. 2018
  - Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry. Leukemia and Lymphoma. 59. 2018
2017
- Journal Articles
  - Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment. JMIR mHealth and uHealth. 5. 2017
  - Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. New England Journal of Medicine. 377. 2017
- Journal Articles Refereed
  - Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. International Journal of Molecular Sciences. 18. 2017
  - Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer. 17. 2017
  - Azacitidine in adult patients with acute myeloid leukemia. Critical Reviews in Oncology Hematology. 116. 2017
  - Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. Nature Communications. 8. 2017
  - Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 129. 2017
  - Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 129. 2017
  - Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. Blood Reviews. 31. 2017
  - Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients. European Journal of Haematology. 99. 2017
  - Early Treatment Intensification With R-ICE And 90Y-Ibritumomab Tiuxetan (Zevalin)-BEAM Stem Cell Transplantation In Patients With High Risk Diffuse Large B-Cell Lymphoma Patients And Positive Interim PET After 4 Cycles Of R-CHOP-14. Haematologica. 102. 2017
  - Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. Hematological Oncology. 35. 2017
  - Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. Journal of Clinical Oncology. 35. 2017
  - Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia. Leukemia and Lymphoma. 58. 2017
  - Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leukemia and Lymphoma. 58. 2017
  - International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology. 28. 2017
  - Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. Journal of Clinical Oncology. 35. 2017
  - Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leukemia and Lymphoma. 58. 2017
  - The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period. Journal of Cancer Survivorship. 11. 2017
  - The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers. Supportive Care in Cancer. 25. 2017
  - The landscape of new drugs in lymphoma. Nature Reviews Clinical Oncology. 14. 2017
  - The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European Journal of Cancer. 75. 2017
  - Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23. 2017
  - Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncology. 18. 2017
  - When to treat patients with relapsed follicular lymphoma. Expert Review of Hematology. 10. 2017
- Journal Articles Unrefereed Letters or Notes
  - Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia. British Journal of Haematology. 176. 2017
  - Obinutuzumab Treatment of Follicular Lymphoma REPLY. New England Journal of Medicine. 377. 2017
  - Primary Breast Lymphoma-Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma. Journal of the National Cancer Institute. 109. 2017
  - The authors reply. New England Journal of Medicine. 377. 2017
- Other Refereed Contribution to Refereed Journals
  - Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?. Annals of Oncology. 28. 2017
  - High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma. British Journal of Haematology. 178. 2017
  - Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors. British Journal of Haematology. 177. 2017
  - Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leukemia and Lymphoma. 58. 2017
- Conference Proceedings
2016
- Journal Articles Refereed
  - Challenging historical perspectives of the 24-h chemotherapy day: Flexible chemotherapy dose-timing guidelines. Asia Pacific Journal of Clinical Oncology. 12. 2016
  - Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy. Leukemia and Lymphoma. 57. 2016
  - Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia 2016
  - Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 27. 2016
  - Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms. Epigenomics. 8. 2016
  - Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 127. 2016
  - Mantle Cell Lymphoma. Journal of Clinical Oncology. 34. 2016
  - Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. Journal of Antimicrobial Chemotherapy. 71. 2016
  - Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia. Seminars in Oncology. 43. 2016
  - Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. Journal of Clinical Oncology. 34. 2016
  - Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. Journal of Antimicrobial Chemotherapy. 71. 2016
  - Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study. American Journal of Hematology. 91. 2016
  - Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine. 374. 2016
  - The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 127. 2016
  - The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. 101. 2016
  - The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Clinical and Experimental Immunology. 183. 2016
  - Transformed Lymphoma. Hematology / Oncology Clinics of North America. 30. 2016
  - Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. British Journal of Haematology. 175. 2016
  - Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncology. 17. 2016
- Journal Articles Unrefereed Letters or Notes
  - Disseminated visceral varicella zoster virus presenting with the constellation of colonic pseudo-obstruction, acalculous cholecystitis and syndrome of inappropriate ADH secretion. Internal Medicine Journal. 46. 2016
  - Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia. Annals of Hematology. 95. 2016
  - New Agents to Treat Chronic Lymphocytic Leukemia REPLY. New England Journal of Medicine. 374. 2016
- Other Refereed Contribution to Refereed Journals
  - Copper deficiency mimicking myelodysplastic syndrome. Leukemia and Lymphoma. 57. 2016
2015
- Journal Articles
  - International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 126. 2015
- Journal Articles Refereed
  - Central Nervous System Prophylaxis in Non-Hodgkin Lymphoma: Who, What, and When? 2015
  - Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer. Journal of Clinical Endocrinology & Metabolism. 100. 2015
  - Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. The Lancet Haematology. 2. 2015
  - Fast-track rapid warfarin reversal for elective surgery: extending the efficacy profile to high-risk patients with cancer. Anaesthesia and Intensive Care. 43. 2015
  - HLA class I associations with EBV+ post-transplant lymphoproliferative disorder. Transplant Immunology. 32. 2015
  - How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?. Leukemia and Lymphoma. 56. 2015
  - Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target. Leukemia and Lymphoma. 56. 2015
  - Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study. Palliative & Supportive Care. 13. 2015
  - Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Annals of Oncology. 26. 2015
  - Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies. British Journal of Haematology. 170. 2015
  - Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis. Leukemia and Lymphoma. 56. 2015
  - Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. The Lancet Haematology. 2. 2015
  - Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 125. 2015
  - Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 20. 2015
  - The molecular pathogenesis of B-cell non-Hodgkin lymphoma. European Journal of Haematology. 95. 2015
  - The utility and limitations of F-18-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leukemia and Lymphoma. 56. 2015
  - Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. The Lancet Haematology. 2. 2015
- Journal Articles Unrefereed Letters or Notes
  - An uncomplicated pregnancy in a woman with smoldering Waldenstrom macroglobulinemia. Leukemia and Lymphoma. 56. 2015
  - Dasatinib therapy can result in significant pulmonary toxicity. American Journal of Hematology. 90. 2015
  - Editor in Chief: Response to Eyre et al. "ALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease". European Journal of Haematology. 94. 2015
  - Large B-cell lymphoma: is the future written in the blood?. Lancet Oncology. 16. 2015
- Other Refereed Contribution to Refereed Journals
  - Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica. 100. 2015
  - Follicular lymphoma: is peripheral blood involvement still an adverse prognostic factor in the rituximab era?. Leukemia and Lymphoma. 56. 2015
  - Immunochemotherapy in Waldenstrom macroglobulinemia - still the backbone of treatment. Leukemia and Lymphoma. 56. 2015
  - Stage I-II follicular lymphoma: an endangered species?. Leukemia and Lymphoma. 56. 2015
2014
- Research Book Chapters
  - B-cell prolymphocytic leukemia (B-PLL) and T-cell prolymphocytic leukemia (T-PLL). Rare Lymphomas. 2014
- Journal Articles Refereed
  - A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. British Journal of Cancer. 111. 2014
  - A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal. 4. 2014
  - A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia. British Journal of Haematology. 167. 2014
  - Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. British Journal of Haematology. 165. 2014
  - Challenges and outcomes of a randomized study of early nutrition support during autologous stem-cell transplantation. CURRENT ONCOLOGY. 21. 2014
  - Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies. Diagnostic Microbiology and Infectious Disease. 79. 2014
  - Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. Biology of Blood and Marrow Transplantation. 20. 2014
  - Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Best Practice & Research: Clinical Haematology. 27. 2014
  - Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy. Annals of Hematology. 93. 2014
  - Optimal approach for high-risk acute promyelocytic leukemia. Current Opinion in Hematology. 21. 2014
  - Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. British Journal of Haematology. 164. 2014
  - Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. Bone Marrow Transplantation. 49. 2014
  - Primary breast lymphoma. Cancer Treatment Reviews. 40. 2014
  - Primary testicular lymphoma. Blood. 123. 2014
  - Prognosis for patients with CML and > 10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 124. 2014
  - R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 99. 2014
  - Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. BMC Pulmonary Medicine. 14. 2014
  - The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma & Leukemia. 14. 2014
  - The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 99. 2014
- Journal Articles Unrefereed Letters or Notes
  - A new prognostic score for CLL. Blood. 124. 2014
  - ABT-199 for chronic lymphocytic leukemia. 2014
  - De novo B-cell prolymphocytic leukemia with central nervous system involvement. Leukemia and Lymphoma. 55. 2014
  - Myeloma and pregnancy: strange bedfellows?. Leukemia and Lymphoma. 55. 2014
  - Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. Blood. 123. 2014
  - Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance. Leukemia and Lymphoma. 55. 2014
- Other Refereed Contribution to Refereed Journals
  - A case of delayed methotrexate clearance following administration of a complementary medication containing chlorophyll. Journal of Oncology Pharmacy Practice. 20. 2014
  - Adding weight to a sinking ship: more reasons not to perform routine surveillance imaging in patients with diffuse large B-cell lymphoma in remission. Leukemia and Lymphoma. 55. 2014
  - Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model. Leukemia Research. 38. 2014
  - Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 124. 2014
  - Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?. Leukemia and Lymphoma. 55. 2014
  - Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 123. 2014
  - Prognostic impact of monocyte count at presentation in mantle cell lymphoma. British Journal of Haematology. 164. 2014
2013
- Journal Articles Refereed
  - A Risk-Adapted Protocol for Delayed Administration of Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma & Leukemia. 13. 2013
  - A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 98. 2013
  - ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine. 19. 2013
  - Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leukemia and Lymphoma. 54. 2013
  - Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Annals of Oncology. 24. 2013
  - Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 121. 2013
  - High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 40. 2013
  - Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. European Journal of Haematology. 91. 2013
  - Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. British Journal of Cancer. 109. 2013
  - Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Annals of Oncology. 24. 2013
  - Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplantation. 48. 2013
  - Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. Journal of Antimicrobial Chemotherapy. 68. 2013
  - Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency. Acta Haematologica. 130. 2013
  - Reproductive concerns of children and adolescents with cancer: challenges and potential solutions. Clinical Oncology in Adolescents and Young Adults. 3. 2013
  - Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma. Journal of Clinical Oncology. 31. 2013
  - Rituximab for the treatment of follicular lymphoma. Future Oncology. 9. 2013
  - Role of Arsenic Trioxide in Acute Promyelocytic Leukemia. Current Treatment Options in Oncology. 14. 2013
  - Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 122. 2013
- Journal Articles Unrefereed Letters or Notes
  - A case of chronic lymphocytic leukemia associated with systemic light chain amyloidosis. Leukemia and Lymphoma. 54. 2013
  - All is not lost - the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab. European Journal of Haematology. 91. 2013
  - Concerns regarding data supporting recent Pneumocystis jirovecii prophylaxis guidelines. Annals of Hematology. 92. 2013
  - Interview: Exploring multiple pathways to find new cures. International Journal of Hematologic Oncology. 2. 2013
  - Treatment of chronic myelomonocytic leukemia with azacitidine. Leukemia and Lymphoma. 54. 2013
- Other Refereed Contribution to Refereed Journals
  - Bone Marrow Biopsy for the Initial Staging of Patients With Lymphoma: Too Soon to Toss the Trephine. Oncology. 27. 2013
  - Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. Leukemia and Lymphoma. 54. 2013
  - Extra-nodal lymphoma in rare localisations: bone, breast and testes. Hematological Oncology. 31. 2013
  - High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?. Leukemia and Lymphoma. 54. 2013
  - Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia and Lymphoma. 54. 2013
  - Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma. Leukemia and Lymphoma. 54. 2013
  - Under-recognition of platelet dysfunction in myelodysplastic syndromes: are we only seeing the tip of the iceberg?. Leukemia and Lymphoma. 54. 2013
  - Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy. British Journal of Haematology. 160. 2013
2012
- Journal Articles Refereed
  - All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 120. 2012
  - Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood. 120. 2012
  - Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial. Annals of Oncology. 23. 2012
  - Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Annals of Oncology. 23. 2012
  - Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 97. 2012
  - Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. Journal of Clinical Oncology. 30. 2012
  - Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study. Leukemia. 26. 2012
  - Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 39. 2012
  - When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?. Internal Medicine Journal. 42. 2012
- Journal Articles Unrefereed Letters or Notes
  - Local experience with the novel human anti-CD20 antibody, ofatumumab, as salvage treatment for patients with heavily pretreated chronic lymphocytic leukaemia. Internal Medicine Journal. 42. 2012
  - Osteolytic bone lesions in non-transformed chronic lymphocytic leukemia are not as rare as suggested. Leukemia and Lymphoma. 53. 2012
  - Paraneoplastic large vessel arteritis complicating myelodysplastic syndrome. Leukemia and Lymphoma. 53. 2012
- Other Refereed Contribution to Refereed Journals
  - Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro. Leukemia. 26. 2012
  - No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia. Leukemia and Lymphoma. 53. 2012
  - Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis. Leukemia and Lymphoma. 53. 2012
  - Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML. Leukemia. 26. 2012
2011
- Journal Articles Refereed
  - A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. Australian Health Review. 35. 2011
  - A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood. 118. 2011
  - An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Internal Medicine Journal. 41. 2011
  - Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes. Cancer. 117. 2011
  - Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Internal Medicine Journal. 41. 2011
  - Lymphoproliferative disorders Part 2 - Chronic lymphocytic leukaemia and follicular lymphoma. Australian Doctor. 2011
  - Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. Journal of Clinical Oncology. 29. 2011
  - Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. The Lancet. 377. 2011
- Journal Articles Unrefereed Letters or Notes
  - ABVD versus BEACOPP for Hodgkin's Lymphoma. New England Journal of Medicine. 365. 2011
  - Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine. European Journal of Haematology. 87. 2011
  - Liver Transplantation in an Adult With Sclerosing Cholangitis due to Multisystem Langerhans Cell Histiocytosis. American Journal of Transplantation. 11. 2011
  - Rituximab maintenance therapy for follicular lymphoma Reply. The Lancet. 377. 2011
- Other Refereed Contribution to Refereed Journals
  - Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplantation. 46. 2011
  - Concomitant FIP1L1--PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib. Leukemia and Lymphoma. 52. 2011
  - Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica. 96. 2011
  - Fludarabine, cyclophosphamide, and rituximab chemotherapy followed by rituximab maintenance in follicular lymphoma: high efficacy may come at a cost?. Leukemia and Lymphoma. 52. 2011
  - Strategies to optimize collection of hematopoietic stem cells in patients with mantle cell lymphoma receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate (Hyper-CVAD) chemotherapy. Leukemia and Lymphoma. 52. 2011
2010
- Journal Articles Refereed
  - Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. The Lancet. 376. 2010
  - Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia. Journal of Clinical Oncology. 28. 2010
  - Effects of azacitidine compared with conventional care regimens in elderly (>= 75 years) patients with higher-risk myelodysplastic syndromes. Critical Reviews in Oncology Hematology. 76. 2010
  - Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenstrom macroglobulinemia. Leukemia and Lymphoma. 51. 2010
  - Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. European Journal of Haematology. 85. 2010
  - Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 24. 2010
  - Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leukemia and Lymphoma. 51. 2010
  - Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. British Journal of Haematology. 149. 2010
  - Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Annals of Oncology. 21. 2010
  - Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 95. 2010
  - The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Annals of Oncology. 21. 2010
  - Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 24. 2010
- Journal Articles Unrefereed Letters or Notes
  - Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. Leukemia and Lymphoma. 51. 2010
  - Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?. Leukemia and Lymphoma. 51. 2010
  - Unresolved issues in the comparison of therapies and determination of responses in Waldenstrom macroglobulinemia. Leukemia and Lymphoma. 51. 2010
  - What is responsible for the recent improvements in outlook for patients with follicular lymphoma?. Leukemia and Lymphoma. 51. 2010
- Other Refereed Contribution to Refereed Journals
  - Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. British Journal of Haematology. 150. 2010
  - Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia. Emerging Infectious Diseases. 16. 2010
  - The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution. Expert Opinion on Biological Therapy. 10. 2010
2009
- Journal Articles
  - Challenges facing survivors of childhood and adolescent cancer. Cancer Forum. 33. 2009
  - Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Internal Medicine Journal. 39. 2009
  - Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC). Leukemia Research. 33. 2009
  - Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q). Leukemia Research. 33. 2009
  - Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA). Leukemia Research. 33. 2009
  - Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia. Journal of Clinical Oncology. 27. 2009
- Journal Articles Refereed
  - 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen. Journal of Clinical Oncology. 27. 2009
  - Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology. 10. 2009
  - Fludarabine combinations for patients with advanced marginal zone lymphomas - best treatment option or too toxic?. British Journal of Haematology. 146. 2009
  - IMPACT OF F-18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY BEFORE AND AFTER DEFINITIVE RADIATION THERAPY IN PATIENTS WITH APPARENTLY SOLITARY PLASMACYTOMA. International Journal of Radiation: Oncology - Biology - Physics. 74. 2009
  - Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices. Supportive Care in Cancer. 17. 2009
  - Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. British Journal of Haematology. 147. 2009
  - Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leukemia and Lymphoma. 50. 2009
  - Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. Annals of Oncology. 20. 2009
  - Progress in primary CNS lymphoma. The Lancet. 374. 2009
  - Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 113. 2009
  - Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator. Leukemia. 23. 2009
  - The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia. 23. 2009
  - Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. Leukemia and Lymphoma. 50. 2009
- Other Refereed Contribution to Refereed Journals
  - HEMATOLOGY Follicular lymphoma: maintenance therapy is (often) indicated. Nature Reviews Clinical Oncology. 6. 2009
  - Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamiderituximab. Leukemia and Lymphoma. 50. 2009
  - Intralesional rituximab for the treatment of localised palatal relapse of follicular lymphoma. Leukemia and Lymphoma. 50. 2009
  - Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leukemia Research. 33. 2009
2008
- Journal Articles
  - 2007: The year in review for Leukemia and Lymphoma. Leukemia and Lymphoma. 49. 2008
  - Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: Efficacy and concomitant cyclosporin A (Mycoses (2007) 50, SUPPL. 1, (24-37)). Mycoses. 51. 2008
  - Happy anniversary to the 10th ICML-International Conference on Malignant Lymphoma in Lugano, 4-7 June 2008 With a personal tribute to the conference president and founder of ICML-Professor Franco Cavalli. Leukemia and Lymphoma. 49. 2008
- Journal Articles Refereed
  - A >= 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leukemia and Lymphoma. 49. 2008
  - A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Annals of Oncology. 19. 2008
  - A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma. 49. 2008
  - Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib. Blood. 111. 2008
  - F-18 fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clinical Lymphoma & Myeloma. 8. 2008
  - Impact of F-18 fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. International Journal of Radiation: Oncology - Biology - Physics. 71. 2008
  - Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 112. 2008
  - Indolent Lymphomas Other than Follicular and Marginal Zone Lymphomas. Hematology / Oncology Clinics of North America. 22. 2008
  - Negative selection of chronic lymphocytic leukaemia cells using a bifunctional rosette-based antibody cocktail. BMC Biotechnology. 8. 2008
  - Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clinical Cancer Research. 14. 2008
  - Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Annals of Oncology. 19. 2008
  - Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Annals of Hematology. 87. 2008
  - Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab. Annals of Oncology. 19. 2008
- Journal Articles Unrefereed
  - Recommendations for the treatment of established fungal infections. Internal Medicine Journal. 38. 2008
  - The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma. British Journal of Haematology. 143. 2008
- Journal Articles Unrefereed Letters or Notes
  - A prospective study of the separate predictive capabilities of (18)F-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-(131)-rituximab radio-immunotherapy. Haematologica. 93. 2008
  - Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib. Leukemia Research. 32. 2008
  - What is the real risk of central nervous system involvement in mantle cell lymphoma?. Leukemia and Lymphoma. 49. 2008
  - What is the role of (18)F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?. Leukemia and Lymphoma. 49. 2008
- Other Refereed Contribution to Refereed Journals
  - Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independent data set. Leukemia. 22. 2008
  - Detection of NPM1 exon 12 mutations and FLT3-internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia. Journal of Hematology & Oncology. 1. 2008
  - Surveillance for catheter-associated bloodstream infection in hematology units: Quantifying the characteristics of a practical case definition. Infection Control and Hospital Epidemiology. 29. 2008
2007
- Journal Articles Refereed
  - BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clinical Cancer Research. 13. 2007
  - Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. Mycoses. 50. 2007
  - Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood. 109. 2007
  - Early therapeutic response assessment by 18 FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leukemia and Lymphoma. 48. 2007
  - Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma. Blood. 110. 2007
  - Mice lacking three myeloid colony-stimulating factors (G-CSF, GM-CSF, and M-CSF) still produce macrophages and Granulocytes and mount sterile model of peritonitis. Journal of Immunology. 178. 2007
  - Overview of early response assessment in lymphoma with FDG-PET.. Cancer Imaging. 7. 2007
  - Radiotherapy for low-grade gastric marginal zone lymphoma: a retrospective study. Internal Medicine Journal. 37. 2007
  - Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. Journal of Clinical Oncology. 25. 2007
  - The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Annals of Hematology. 86. 2007
  - Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. European Journal of Haematology. 79. 2007
  - Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica. 92. 2007
- Other Refereed Contribution to Refereed Journals
  - Surveillance of second cancer after previous childhood cancer treatment. Australian Family Physician. 36. 2007
  - The late effects clinic in action: Ror survivors of childhood malignancy. Acta Oncologica. 46. 2007
2006
- Journal Articles Refereed
  - A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with Hematologic malignancies. Clinical Infectious Diseases. 43. 2006
  - Clonal "devolution" in a case of essential thrombocythemia with transformation from refractory cytopenia with multilineage dysplasia to acute myeloid leukemia. Leukemia and Lymphoma. 47. 2006
  - Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase. Leukemia and Lymphoma. 47. 2006
  - Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring. Journal of Clinical Oncology. 24. 2006
  - Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8(+) T-cell function in Hodgkin lymphoma patients. Blood. 108. 2006
  - Extra-pulmonary aspects of acquired pulmonary alveolar proteinosis as predicted by granulocyte-macrophage colony-stimulating factor-deficient mice. Respirology. 11. 2006
  - Fertility preservation in female oncology patients. Australian and New Zealand Journal of Obstetrics and Gynaecology. 46. 2006
  - Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer. 106. 2006
  - Functional reversion of antigen-specific CD8(+) T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. Journal of Immunology. 177. 2006
  - Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. British Journal of Cancer. 94. 2006
  - Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology. 24. 2006
  - Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clinical Cancer Research. 12. 2006
  - Primary non-Hodgkin's lymphoma of the breast: Retrospective analysis of prognosis and patterns of failure in two Australian centers. Clinical Lymphoma & Myeloma. 6. 2006
  - Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia and Lymphoma. 47. 2006
  - The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematological Oncology. 24. 2006
  - The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function. Leukemia Research. 30. 2006
  - The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer. 107. 2006
  - The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. European Journal of Haematology. 76. 2006
- Journal Articles Unrefereed
  - Defining the cost of cure: Infertility among female survivors of lymphoma. Leukemia and Lymphoma. 47. 2006
- Journal Articles Unrefereed Letters or Notes
  - 101 years of McCrae's (not Auer's) rods. British Journal of Haematology. 133. 2006
  - Preliminary experience of F-18-fluorodeoxyglucose positron emission tomography in Castleman's disease. Leukemia and Lymphoma. 47. 2006
  - The infectious consequences of rituximab addition to fludarabine-containing regimens. Blood. 107. 2006
- Other Refereed Contribution to Refereed Journals
  - A denileukin diftitox (Ontak) associated retinopathy?. British Journal of Ophthalmology. 90. 2006
  - Adolescent and young adult cancer: a revolution in evolution?. Internal Medicine Journal. 36. 2006
  - Alveolar soft-part sarcoma - A cardiac metastasis as a rare site of relapse. American Journal of Clinical Oncology - Cancer Clinical Trials. 29. 2006
  - Cardiac involvement in Henoch-Schonlein purpura. Internal Medicine Journal. 36. 2006
  - Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 108. 2006
  - Primary skeletal muscle marginal zone lymphoma with persistent tissue tropism and PET-avidity. Leukemia and Lymphoma. 47. 2006
  - Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. British Journal of Haematology. 132. 2006
  - Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. Cancer Genetics and Cytogenetics. 171. 2006
  - Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica. 91. 2006
2005
- Journal Articles
  - A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clinical Cancer Research. 11. 2005
  - A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leukemia and Lymphoma. 46. 2005
  - A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma. Leukemia and Lymphoma. 46. 2005
  - A phase Ib clinical trial of PV70I, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy. Biology of Blood and Marrow Transplantation. 11. 2005
  - Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia. Leukemia and Lymphoma. 46. 2005
  - Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention. Medical Journal of Australia. 183. 2005
  - Could lymphoma be the underlying disease in this patient with pyrexia of unknown origin?. Internal Medicine Journal. 35. 2005
  - Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: Role of rituximab, high-dose therapy, and allogeneic stem cell transplantation. Leukemia and Lymphoma. 46. 2005
  - Early B-cell chronic lymphocytic leukemia presenting as cutaneous lesions with a normal peripheral blood lymphocyte count. Journal of the American Academy of Dermatology. 53. 2005
  - Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.. Clinical Lymphoma & Myeloma. 6. 2005
  - Lack of apoptosis of Sezary cells in the circulation following oral bexarotene therapy. British Journal of Dermatology. 152. 2005
  - Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.. Clinical Lymphoma. 5. 2005
  - Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. Journal of Clinical Oncology. 23. 2005
  - Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leukemia and Lymphoma. 46. 2005
- Journal Articles Refereed
  - An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. British Journal of Cancer. 92. 2005
  - Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review. Leukemia and Lymphoma. 46. 2005
  - Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leukemia and Lymphoma. 46. 2005
  - Initial staging of lymphoma with positron emission tomography and computed tomography. Seminars in Nuclear Medicine. 35. 2005
  - Posttraumatic growth following a cancer diagnosis: Do world assumptions contribute?. Traumatology. 11. 2005
- Journal Articles Unrefereed Letters or Notes
  - Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. Annals of Hematology. 84. 2005
- Other Refereed Contribution to Refereed Journals
  - Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica. 90. 2005
  - Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica. 90. 2005
  - Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. British Journal of Haematology. 130. 2005
2004
- Journal Articles
  - Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Annals of Oncology. 15. 2004
  - High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood. 103. 2004
  - Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Annals of Oncology. 15. 2004
  - Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. British Journal of Haematology. 127. 2004
  - New treatment approaches to indolent non-Hodgkin's lymphoma. Seminars in Oncology. 31. 2004
  - Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. New England Journal of Medicine. 351. 2004
- Journal Articles Refereed
  - A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. European Journal of Haematology. 72. 2004
  - A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer. 101. 2004
  - Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer. 100. 2004
  - Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells. British Journal of Haematology. 126. 2004
  - Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 104. 2004
- Journal Articles Unrefereed Letters or Notes
  - Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Clinical Cancer Research. 10. 2004
- Other Refereed Contribution to Refereed Journals
  - Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sezary syndrome. European Journal of Haematology. 73. 2004
  - Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Internal Medicine Journal. 34. 2004
  - Leukaemic subtype of marginal zone lymphoma: A presentation of three cases and literature review. Leukemia and Lymphoma. 45. 2004
  - Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukemia. 18. 2004
  - Pulmonary alveolar proteinosis. Clinics in Chest Medicine. 25. 2004
  - Pulmonary alveolar proteinosis. What is the role of GM-CSF in disease pathogenesis and treatment?. Treatments in Respiratory Medicine. 3. 2004
  - Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. American Journal of Hematology. 77. 2004
2003
- Journal Articles
  - Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology. 21. 2003
  - Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. Journal of Clinical Oncology. 21. 2003
  - Progressive multifocal leukoencephalopathy complicating Waldenstrom's macroglobulinaemia. Leukemia and Lymphoma. 44. 2003
- Journal Articles Refereed
  - A case of clinical indolent natural killer cell lineage large granular lymphocytic leukemia in a patient with rheumatoid arthritis. Leukemia and Lymphoma. 44. 2003
  - ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: Report of 6 cases. Blood. 102. 2003
  - Clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer and World Health Organization classifications.. Australasian Journal of Dermatology. 44. 2003
  - Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 102. 2003
  - Frequent impact of F-18fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clinical Lymphoma. 4. 2003
  - Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 17. 2003
  - Legionella pneumophila mip gene sequencing to investigate a cluster of pneumonia cases. Pathology. 35. 2003
  - Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood. 102. 2003
  - Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma. Annals of Oncology. 14. 2003
  - Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax. 58. 2003
  - Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia. 17. 2003
  - Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. European Journal of Haematology. 71. 2003
- Journal Articles Unrefereed
  - Management of the primary cutaneous lymphomas.. Australasian Journal of Dermatology. 44. 2003
- Journal Articles Unrefereed Letters or Notes
  - Dosing schedule of oral valacyclovir for prevention of herpes simplex virus. Bone Marrow Transplantation. 32. 2003
  - Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide. British Journal of Haematology. 123. 2003
2002
- Journal Articles
  - BAL findings in a patient with pulmonary alveolar proteinosis successfully treatelwulith GM-CSF. Thorax. 57. 2002
  - CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy. 4. 2002
  - Graft versus Burkitt's lymphoma effect after allogeneic marrow transplantation. Leukemia and Lymphoma. 43. 2002
  - Insights into the molecular pathogenesis of follicular lymphoma, arising from analysis of geographic variation. Blood. 99. 2002
  - Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leukemia and Lymphoma. 43. 2002
  - Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy. 4. 2002
  - Pulmonary alveolar proteinosis - Progress in the first 44 years. American Journal of Respiratory and Critical Care Medicine. 166. 2002
  - Role of (18)FDG-positron emission tomography scanning in the management of histiocytosis. Leukemia and Lymphoma. 43. 2002
  - Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Annals of Oncology. 13. 2002
- Journal Articles Refereed
  - Cisplatin, fludarabine, and cytarabine - A novel, pharmacologically designed salvage therapy for patients with refractory histologically aggressive or mantle cell non-Hodgkin lymphoma. Cancer. 94. 2002
  - Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. American Journal of Medicine. 112. 2002
- Journal Articles Unrefereed
  - Discordant response to chemotherapy detected by PET scanning - Unveiling of a second primary cancer. American Journal of Clinical Oncology - Cancer Clinical Trials. 25. 2002
- Other Refereed Contribution to Refereed Journals
  - Diffuse large B-cell non-Hodgkin's lymphoma presenting as Sister Joseph's nodule. Leukemia and Lymphoma. 43. 2002
  - Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia. European Journal of Haematology. 69. 2002
2001
- Journal Articles
  - Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplantation. 28. 2001
  - CliniMACS CD34-selected cells to support high-dose therapy. Transfusion and Apheresis Science. 24. 2001
  - Commentary on "High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma". Clinical Lymphoma. 2. 2001
  - Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: Role of liposomal amphotericin B and GM-CSF. Leukemia and Lymphoma. 42. 2001
  - Hodgkin's disease complicated by the nephrotic syndrome in a man with Kugelberg-Welander disease. Leukemia and Lymphoma. 42. 2001
  - Management of localized low-grade follicular lymphomas.. Australasian Radiology. 45. 2001
  - Ovarian tissue cryopreservation for cancer patients: who is appropriate?. Reproduction, Fertility and Development. 13. 2001
  - Pegylated liposomal doxorubicin in the treatment of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology. 44. 2001
  - Successful treatment of rhinocerebral zygomycosis using liposomal nystatin. Leukemia and Lymphoma. 42. 2001
- Journal Articles Refereed
  - Diffuse large cell lymphoma and t(8;22) (q24;q11) in a patient with idiopathic CD4+T-lymphopenia. Leukemia and Lymphoma. 41. 2001
  - Fludarabine and mitoxantrone: Effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Annals of Oncology. 12. 2001
  - High-dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience. Internal Medicine Journal. 31. 2001
  - Primary large-cell non-Hodgkin's lymphoma of the testis: A retrospective analysis of patterns of failure and prognostic factors. Clinical Lymphoma. 2. 2001
  - Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. American Journal of Respiratory and Critical Care Medicine. 163. 2001
- Conference Proceedings
  - A review of the Australian and New Zealand Apheresis Association and register of procedures and incidents. Transfusion and Apheresis Science. 2001
2000
- Journal Articles
  - Deafness from eighth cranial nerve involvement in a patient with large-cell transformation of mycosis fungoides. European Journal of Haematology. 64. 2000
  - Docetaxel effectively mobilizes peripheral blood CD34(+) cells. Bone Marrow Transplantation. 26. 2000
  - Efficacy of fludarabine & cyclophosphamide therapy for patients with relapsed and refractory low-grade lymphoproliferative disorders. Blood. 96. 2000
  - Paraffin section immunotyping of leukaemias. British Journal of Haematology. 109. 2000
  - Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. Bone Marrow Transplantation. 26. 2000
  - Serological diagnosis of idiopathic pulmonary alveolar proteinosis. American Journal of Respiratory and Critical Care Medicine. 162. 2000
1999
- Journal Articles
  - 'Mini-allografts' for haematological malignancies: an alternative to conventional myeloablative marrow transplantation. Australian and New Zealand Journal of Medicine. 29. 1999
  - Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stent cells for relapsed leukaemia and lymphoma. Bone Marrow Transplantation. 23. 1999
  - Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study. Annals of Oncology. 10. 1999
  - Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia. 13. 1999
  - Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: A phase II study. Leukemia and Lymphoma. 36. 1999
1998
- Journal Articles
  - Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia. 12. 1998
  - Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis. Blood. 92. 1998
  - Hypercalcemia of malignancy. American Journal of Medicine. 105. 1998
  - Long-term pamidronate in multiple myeloma. Journal of Clinical Oncology. 16. 1998
  - Progress in management of acute myeloid leukaemia (AML) in Australia since 1980: a single institution retrospective study. Australian and New Zealand Journal of Medicine. 28. 1998
1997
- Journal Articles
  - Bilateral fracture of the mandible in chronic lymphocytic leukaemia. Case report. Australian Dental Journal. 42. 1997
  - Case/control study of the role of splenectomy in chronic lymphocytic leukemia. Journal of Clinical Oncology. 15. 1997
  - Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease. American Journal of Medicine. 102. 1997
  - Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival. Blood. 90. 1997
  - Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Annals of Internal Medicine. 127. 1997
  - Prolonged disease-free survival with specific re-induction therapy in acute myeloid leukaemia relapsing following bone marrow transplantation. Australian and New Zealand Journal of Medicine. 27. 1997
  - Regression of gastric lymphoma with therapy for Helicobacter pylori infection. Annals of Internal Medicine. 127. 1997
  - Response duration and recovery of CD4(+) lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia. 11. 1997
  - Role of splenectomy in chronic lymphocytic leukemia. Journal of the American College of Surgeons. 185. 1997
  - Splenomegaly, eosinophilia, and pruritis: Hodgkin's disease, or?. Blood. 90. 1997
1996
- Journal Articles
  - Combined modality therapy for stage I-II MALT lymphoma and mantle cell lymphoma. Annals of Oncology. 7. 1996
  - Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. New England Journal of Medicine. 335. 1996
  - High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Annals of Oncology. 7. 1996
  - Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: Implications for a continuous infusion schedule. Clinical Cancer Research. 2. 1996
  - Interleukin-6: biologic properties and role in lymphoproliferative disorders.. Cancer Treatment and Research. 84. 1996
  - Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy. British Journal of Haematology. 94. 1996
1995
- Journal Articles
  - BONE-MARROW TRANSPLANTATION VERSUS CHEMOTHERAPY IN NON-HODGKINS-LYMPHOMA. New England Journal of Medicine. 333. 1995
  - PARATHYROID-HORMONE RELATED PROTEIN IN HYPERCALCEMIA IN CLL. British Journal of Haematology. 89. 1995
  - RESPONSE TO INTERFERON-ALPHA IN PATIENTS WITH HAIRY-CELL LEUKEMIA RELAPSING AFTER TREATMENT WITH 2-CHLORODEOXYADENOSINE. Leukemia. 9. 1995
  - SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH PROGNOSIS IN DIFFUSE LARGE-CELL LYMPHOMA. Journal of Clinical Oncology. 13. 1995
  - SERUM LEVELS OF INTERLEUKIN-10 IN PATIENTS WITH DIFFUSE LARGE-CELL LYMPHOMA - LACK OF CORRELATION WITH PROGNOSIS. Blood. 85. 1995
  - SURVIVAL OF YOUNG-PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA FAILING FLUDARABINE THERAPY - A BASIS FOR THE USE OF MYELOABLATIVE THERAPIES. Leukemia and Lymphoma. 18. 1995
  - THE CONTRIBUTION OF AUER RODS TO THE CLASSIFICATION AND PROGNOSIS OF MYELODYSPLASTIC SYNDROMES. Leukemia and Lymphoma. 17. 1995
1994
- Journal Articles
  - 2-CHLORODEOXYADENOSINE INDUCES DURABLE REMISSIONS AND PROLONGED SUPPRESSION OF CD4(+) LYMPHOCYTE COUNTS IN PATIENTS WITH HAIRY-CELL LEUKEMIA. Blood. 83. 1994
  - AN EFFECTIVE AGE-UNRESTRICTED M-AMSA-BASED 2ND-LINE REGIMEN FOR POOR-PROGNOSIS ACUTE MYELOID-LEUKEMIA. European Journal of Haematology. 52. 1994
  - CALCITRIOL PRODUCTION IN HYPERCALCEMIC AND NORMOCALCEMIC PATIENTS WITH NON-HODGKIN-LYMPHOMA. Annals of Internal Medicine. 121. 1994
  - HYPERCALCEMIA IN ACUTE LYMPHOBLASTIC-LEUKEMIA. Leukemia Research. 18. 1994
  - INVESTIGATION OF KARYOTYPIC, MORPHOLOGIC AND CLINICAL-FEATURES IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA BLAST CELLS EXPRESSING THE NEURAL CELL-ADHESION MOLECULE (CD56). Leukemia. 8. 1994
  - LYMPHOMATOUS PRESENTATION OF CD4+/CD8+ HTLV-1-RELATED ADULT T-CELL LEUKEMIA-LYMPHOMA IN AN IRANIAN WOMAN. Leukemia and Lymphoma. 12. 1994
  - REFRACTORY CHRONIC LYMPHOCYTIC-LEUKEMIA COMPLICATED BY HYPERCALCEMIA TREATED WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION - CASE-REPORT AND REVIEW. American Journal of Clinical Oncology - Cancer Clinical Trials. 17. 1994
1993
- Journal Articles
  - ACUTE-LEUKEMIA COMPLICATING BONE-MARROW HYPOPLASIA IN AN ADULT WITH SHWACHMAN-SYNDROME. Leukemia and Lymphoma. 12. 1993
  - CALCITRIOL - THE MAJOR HUMORAL MEDIATOR OF HYPERCALCEMIA IN HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMAS. Blood. 82. 1993
  - HYPERCALCEMIA IN THE BLASTIC PHASE OF CHRONIC MYELOID-LEUKEMIA ASSOCIATED WITH ELEVATED PARATHYROID HORMONE-RELATED PROTEIN. Leukemia. 7. 1993
  - INDUCTION OF HYPOMAGNESEMIA DURING AMSACRINE TREATMENT. American Journal of Hematology. 42. 1993
  - MENTAL NEUROPATHY (NUMB CHIN SYNDROME) - A HARBINGER OF TUMOR PROGRESSION OR RELAPSE. Cancer. 71. 1993
  - THE PROGNOSTIC-SIGNIFICANCE OF AUER RODS IN MYELODYSPLASIA. British Journal of Haematology. 85. 1993
1992
- Journal Articles
  - MECHANISMS OF HYPERCALCEMIA IN LYMPHOMAS. Annals of Oncology. 3. 1992
  - PROPHYLACTIC PLATELET TRANSFUSION IN ACUTE-LEUKEMIA. The Lancet. 339. 1992

Research

Investigator on

Grant
- CIRCULATING TUMOUR DNA TO MONITOR TREATMENT RESPONSE AND RESISTANCE IN CHRONIC LYMPHOCYTIC LEUKAEMIA (Project Grants) awarded by NHMRC 2016 - 2019
- RATIONAL COMBINATION THERAPIES FOR JAK-DRIVEN HAEMATOLOGICAL MALIGNANCIES (Grants-in-Aid) awarded by CANCER COUNCIL VICTORIA 2015 - 2017
- CIRCULATING TUMOR DNA TO MONITOR TREATMENT RESPONSE AND RESISTANCE IN MANTLE CELL LYMPHOMA (The Quest for Cures Research Grant) awarded by LEUKEMIA & LYMPHOMA SOCIETY 2014 - 2018
- A randomised controlled trial of a bone formation stimulating hormone to reverse osteonecrosis of the jaw in cancer patients (Project Grants) awarded by NHMRC 2012 - 2015
- CROSS DISCIPLINARY STUDY OF PHARMACOLOGIC FACTORS AFFECTING CANCER OUTCOMES IN ADOLESCENTS AND YOUNG ADULTS (AYA) (Clinical Trials Pilot Study Grant) awarded by VIC CANCER AGENCY 2009 - 2011
- NOVEL COMBINATION THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA (Cancer Aust Priority-Driven Collaborative Cancer Research Scheme) awarded by CANCER AUSTRALIA 2008 - 2010
- INFRASTRUCTURE SUPPORT FOR THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA GROUP (ALLG) TRIAL CENTRE (Enabling Grant) awarded by NHMRC 2006 - 2011

Contact Details
- seymourj@unimelb.edu.au
Graduate Study
- - Interested in Graduate Study at Melbourne? Next steps:
    - Graduate Research Programs in Medicine Dentistry and Health Sciences
Visualization Gallery
- Collaboration
  - Co-Author Network
  - Co-Investigator Network
- Research Area Visualizations
  - Map Of Science